2021年1月3日,Amberstone Biosciences公司宣布完成1200萬(wàn)美元的A輪融資。融資所獲得的資金將用于將其高度差異化的腫瘤微環(huán)境激活療法(T-MATE)研發(fā)項(xiàng)目推進(jìn)到支持IND申請(qǐng)研究階段,它們包括被腫瘤微環(huán)境激活的雙特異性抗體和免疫細(xì)胞因子。
Amberstone的T-MATE治療分子通過(guò)其基于微流控技術(shù)的藥物發(fā)現(xiàn)平臺(tái)AmberFlow研發(fā)。該平臺(tái)能夠在可調(diào)節(jié)微環(huán)境中對(duì)單細(xì)胞功能進(jìn)行分析,并高效地分離罕見(jiàn)的高質(zhì)量抗體候選藥物。
參考資料:
[1] Amberstone Biosciences Secures $12 Million Series A Financing to Advance Immuno-Oncology Pipeline of Tumor Microenvironment Activated Therapeutics. Retrieved January 3, 2021, from https://www.businesswire.com/news/home/20220103005033/en/Amberstone-Biosciences-Secures-12-Million-Series-A-Financing-to-Advance-Immuno-Oncology-Pipeline-of-Tumor-Microenvironment-Activated-Therapeutics
(原文有刪減)